Meeting
2017 Genitourinary Cancers Symposium
Second line axitinib in metastatic renal cell carcinoma: Evaluation of prognostic factors influencing outcome.
Authors
Helen Brooks
Bristol Cancer Institute, Bristol, United Kingdom
Helen Brooks , Amarnath Challapalli , Hannah Reed , Susan Masson , Serena Hilman , Amit Bahl
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Penile, Urethral, and Testicular Cancers; Renal Cell Cancer
Track
Renal Cell Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 495)
DOI
10.1200/JCO.2017.35.6_suppl.495
Abstract #
495
Poster Bd #
F10
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).
First Author: Chun Loo Gan
Poster
2018 Genitourinary Cancers Symposium
A FavorAx study of axitinib in favorable risk patients with metastatic renal cell carcinoma.
First Author: Ilya Tsimafeyeu
Poster
2024 ASCO Genitourinary Cancers Symposium
Treatment-free survival after first-line therapies for metastatic renal cell carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) analysis.
First Author: Mehul Gupta
Poster
2023 ASCO Genitourinary Cancers Symposium
Impact of number of treatment lines following first-line (1L) immuno-oncology (IO) combination on overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC).
First Author: Audreylie Lemelin